TG (Thyroglobulin)

This study showed that the incidence of thyroid cancer has increased in solid-organ transplants, but mortality rates from thyroid cancer have not been affected.

Clinically and imaging-detected thyroid cancers differ in clinicopathological profiles but show comparable long-term outcomes. These results suggest that early detection of thyroid cancer through imaging may not necessarily translate into a more favorable prognosis under risk-stratified management.

Short-course, genotype-directed MAPK inhibition effectively restored iodine avidity and enabled safe, dosimetry-guided radioiodine therapy in a real-world RAIR-DTC cohort. Early structural responses were frequent, toxicity was minimal, and selected patients benefited from repeat redifferentiation cycles. These findings support the use of redifferentiation as a practical bridge to effective RAI and underscore the value of individualized dosimetry in modern RAIR-DTC management.

The median PFS of BIR patients was 64.4 months and the 5-year PFS rate was 60.4%. sTg≥50.0 ng/mL and T3b-T4 stage are robust, clinically accessible markers identifying PD among BIR patients, warranting intensified surveillance and potentially earlier therapeutic reconsideration.

Measuring Tg and Tg antibody levels post-TL can provide a baseline for future reference. However, this case illustrates that high levels of Tg can be seen in the absence of thyroid cancer and therefore cannot reliably predict the risk of recurrence.

Histologically after core and excisional biopsy, a benign adenomyoepithelioma was confirmed. This is, to our knowledge, the first reported iodine avide adenomyoepithelioma and highlights a rare diagnostic pitfall.

The relationship between nodule size and malignancy is known, but elevated thyroglobulin levels have been found to be an independent risk factor for malignancy in indeterminate nodules. Although it needs to be generalized with more data, it is an inexpensive and simple diagnostic test that could guide us in patients with indeterminate cytologic findings.

RFA is a safe and effective treatment for patients with low-risk follicular neoplasm (SUVmax value < 5) in medium-term follow-up. For patients who are either ineligible for or prefer to avoid surgery, RFA presents a feasible alternative treatment option.

MRI was immediately added, and PET/MRI fusion image localized an air-containing lesion interlinked with esophagus with enhanced T2 hyperintense mucosal signal, indicating an inflammatory esophageal diverticulum, which was subsequently verified by endoscopy. This case highlights the added value of PET/MRI image fusion in cases with inconclusive 18F-FDG PET/CT findings, requiring no additional tests and utilizing existing software, thereby minimizing the need for invasive procedures.

The rationales for lack of significant correlation in the high-risk group DTC were discussed. Thyroid uptake quantification may serve as a feasible substitute for Tg measurements in post-ablation follow-up, offering potential for predicting disease recurrence.

TG can be determined as a tumor marker in these patients under required levothyroxine treatment at TSH suppressive doses...Heterophilic antibodies are another important source of interference. Mass spectroscopic TG determination is a more complex alternative that can be used in inconclusive cases.

TC-derived plasma sEVs promoted TC cell proliferation, migration, invasion, and TC xenograft growth. EPCAM+ sEVs could serve as a promising biomarker for the early diagnosis of TC and perform better in monitoring post-operative remission of TC than serum Tg.